Safety and Efficacy of Conivaptan in Hyponatremic Patients With Symptomatic Acute Decompensated Heart Failure (ADHF)

Summary

This study will evaluate the safety and effectiveness of Conivaptan, a vasopressin antagonist, in the treatment of hyponatremic subjects having symptomatic acute decompensated heart failure (ADHF).

Timeline

Start

2009-04

Primary completion

2009-08

Completion

2009-08

Outcome

Outcome not reported

Stopped (Enrollment): “The clinical study has been terminated based on difficulties to enroll eligible subjects per protocol inclusion and exclusion criteria.”

Drugs

Indications